Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
SAN ANTONIO, Nov. 15, 2016 -- bioAffinity Technologies announced that the government of the Hong Kong Special Administrative Region has awarded a Certificate of Grant of Standard Patent for the Company’s proprietary CyPath© technology for the early detection of lung cancer.
The Hong Kong patent, titled “System and Method for Analyzing Samples Labeled with 5, 10, 15, 20 Tetrakis (4-Carboxyphenyl) Porphine (TCPP),” grants protection to 2030 for bioAffinity’s platform test for early cancer detection. bioAffinity’s intellectual property (IP) portfolio now consists of 43 awarded patents in 22 countries.
bioAffinity’s porphyrin-based CyPath© bio-label preferentially binds to cancer cells, giving them a distinctive fluorescence that is detectable and measurable by an imaging system. CyPath© Lung, bioAffinity’s initial product, is designed to be a highly accurate, non-invasive, early-stage lung cancer diagnostic for use by those at risk for lung cancer.
“Lung cancer is the leading cause of cancer deaths worldwide, and as much as 85 percent of lung cancers are attributable to smoking,” bioAffinity President and CEO Maria Zannes said. “With an estimated 370 million smokers in China, Hong Kong and Japan, our technology can have a significant positive impact on early detection and more effective treatment of the disease in Asia, the world’s largest market. We are pleased to add the Hong Kong patent to our existing patents in China and Japan.”
bioAffinity is focused on the commercialization of accurate, non-invasive diagnostics and life-saving targeted therapeutics for multiple cancers. CyPath© Lung is a simple and cost-effective diagnostic, which will make it particularly effective in countries with large populations and a broad demographic.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas Health Science Center at San Antonio through a collaborative research agreement. The Company’s platform technology will be developed to diagnose, monitor and treat many cancers.
Contact: Maria Zannes, 505.400.9747
